argenx engineers first-in-class therapies for rare diseases – where underserved patients need breakthroughs and the healthcare community needs options. Our franchise-focused approach to . Feb 27, 2026 · At argenx, our commitment to ESG is about measuring our progress as a business based on core components that will sustain us on our path to be an integrated, immunology company. At argenx, we are redefining how a biotech company can advance science and deliver innovative treatments. We're enabling new ways of working with partners, patients and each other.
Apr 25, 2008 · On May 5, 2017, we transferred the legal ownership of all intellectual property rights of argenx SE to argenx BV, effective retroactively as of January 1, 2017. argenx Announces Results of Extraordinary General Meeting of Shareholders October 30, 2025 argenx Reports Third Quarter 2025 Financial Results and Provides Business Update October 29, 2025 . We embrace the power of the collective – together we are better. At argenx, we’ve created an antibody innovation ecosystem where pioneering scientists and antibody engineers work side-by-side to .
The name argenx comes from the ancient myth of the Argonauts – one of the first stories on record recognizing the power of the team rather than one hero. The Argonauts set out in a small boat on a . The science of co-creation drives our quest to engineer life-changing immunology solutions, the resilient spirit of patients fuels our urgency to deliver them. By combining llama-derived V regions with fully human Fc regions, argenx creates a library of human-like antibodies that can be tested across multiple epitopes to find the right balance of potency, safety, .
argenx is committed to improving the lives of people suffering from severe autoimmune diseases. We aim to do this in partnership; by listening to patients, supporters and advocacy communities and .
- Argenx | Pipeline - Differentiated Immunology Solutions.
- At argenx, our commitment to ESG is about measuring our progress as a business based on core components that will sustain us on our path to be an integrated, immunology company.
- Company Profile - argenx Annual Report 2024.
Argenx | Products - Approved for use in the United States. This indicates that "argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline" should be tracked with broader context and ongoing updates.
Argenx | Innovation - The Science of Collaboration. For readers, this helps frame potential impact and what to watch next.
FAQ
What happened with argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline?
Our Commitment to Patients - Argenx.
Why is argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline important right now?
It matters because it may affect decisions, expectations, or near-term outcomes.
What should readers monitor next?
Watch for official updates, verified data changes, and follow-up statements from primary sources.
